Volume 32, Number 3—March 2026
Dispatch
Home-Based Monitoring of Treatment-Related Adverse Events during Drug-Resistant Tuberculosis Treatment, India, 2020–2024
Minal Ahson, Daksha Shah, Sampada Bhide, Rajesh Deshmukh, Jonathan P. Smith, Smita Waghmare, Satish Kaipilyawar, Varsha Puri, Dilip K. Khetade, Vijay Yeldandi, Anand Date, Patrick K. Moonan1, and Christine S. Ho1
Table
Frequency, severity, and treatment modification of reported adverse events during home-based monitoring of drug-resistant tuberculosis treatment, Dharavi, Mumbai, India, 2020‒June 2024*
| Adverse event† | Total | Severity |
Required treatment modification | ||
|---|---|---|---|---|---|
| Mild | Moderate | Severe | |||
| Neurologic | 292 (21) | 86 (29) | 203 (70) | 3 (1) | 52 (18) |
| Tingling, pain, or numbness in hands or feet | 148 (11) | 48 (32) | 99 (67) | 1 (1) | 34 (23) |
| Visual disturbances | 54 (4) | 15 (28) | 39 (72) | 0 | 12 (22) |
| Headache | 34 (3) | 7 (21) | 26 (76) | 1 (3) | 3 (9) |
| Dizziness | 27 (2) | 8 (30) | 19 (70) | 0 | 0 |
| Hearing loss | 16 (1) | 1 (6) | 15 (94) | 0 | 1 (6) |
| Ringing in ears | 12 (1) | 7 (58) | 5 (42) | 0 | 2 (17) |
| Seizure |
1 (<1) |
0 |
0 |
1 (100) |
0 |
| Gastrointestinal | 309 (22) | 123 (40) | 175 (57) | 11 (4) | 12 (4) |
| Nausea, vomiting | 163 (12) | 79 (48) | 80 (49) | 4 (3) | 6 (4) |
| Loss of appetite | 68 (5) | 24 (35) | 43 (63) | 1 (2) | 3 (4) |
| Abdominal pain | 51 (4) | 13 (25) | 33 (65) | 5 (10) | 2 (4) |
| Diarrhea | 13 (1) | 3 (23) | 10 (77) | 0 | 1 (8) |
| Constipation | 8 (<1) | 2 (25) | 6 (75) | 0 | 0 |
| Difficulty urinating | 4 (<1) | 1 (25) | 2 (50) | 1 (25) | 0 |
| Yellowish discoloration of skin and eyes |
2 (<1) |
1 (50) |
1 (50) |
0 |
0 |
| Musculoskeletal | 174 (12) | 66 (38) | 108 (62) | 0 | 23 (13) |
| Joint pain | 168 (12) | 65 (39) | 103 (61) | 0 | 22 (13) |
| Neck, face swelling |
6 (<1) |
1 (17) |
5 (83) |
0 |
1 (17) |
| Behavioral | 48 (4) | 18 (38) | 26 (54) | 4 (8) | 10 (21) |
| Psychosis | 10 (1) | 6 (60) | 4 (40) | 0 | 2 (20) |
| Changes in behavior | 18 (1) | 6 (33) | 11 (61) | 1 (6) | 5 (28) |
| Sleep disturbances | 8 (<1) | 3 (38) | 5 (62) | 0 | 1 (13) |
| Depression or suicidal ideation |
12 (1) |
3 (25) |
6 (50) |
3 (25) |
2 (17) |
| Dermatologic | 37 (3) | 21 (57) | 16 (43) | 0 | 3 (8) |
| Skin rash or itching |
37 (3) |
21 (57) |
16 (43) |
0 |
3 (8) |
| Cardiologic | 99 (7) | 28 (28) | 66 (67) | 5 (5) | 5 (5) |
| Abnormal electrocardiogram | 39 (3) | 20 (51) | 19 (49) | 0 | 0 |
| Fatigue | 38 (3) | 4 (11) | 31 (82) | 3 (8) | 3 (8) |
| Palpitations | 22 (2) | 4 (18) | 16 (73) | 2 (9) | 2 (9) |
| Other, unspecified |
451 (32) |
139 (31) |
284 (63) |
28 (6) |
21 (5) |
| Total | 1,410 | 481 (34) | 878 (62) | 51 (4) | 126 (9) |
*Values are no. (%). †Patients could experience multiple events.
1These authors contributed equally to this article.
Page created: February 20, 2026
Page updated: March 20, 2026
Page reviewed: March 20, 2026
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.